Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glomerular filtration rate (eGFR) ≥25 ml min-1 1.73 m-2 and urine albumin-to-creatinine ratio (UACR) ≥30 and <3,500 mg g-1) and body mass index ≥27 kg m-2. Participants were randomized to semaglutide 2.4 mg per week or placebo. The primary endpoint was percentage change from baseline in UACR at week 24. Safety was monitored throughout. Overall, 125 participants were screened, of whom 101 were randomized to semaglutide (n = 51) or placebo (n = 50). Mean age was 55.8 (s.d. 12) years; 40 participants (39.6%) were female; median UACR was 251 mg g-1 (interquartile range 100, 584); mean eGFR was 65.0 (s.d. 25) ml min-1 1.73 m-2; and mean body mass index was 36.2 (s.d. 5.6) kg m-2. Chronic glomerulonephritis (n = 25) and hypertensive CKD (n = 27) were the most common CKD etiologies. Treatment for 24 weeks with semaglutide compared to placebo reduced UACR by -52.1% (95% confidence interval -65.5, -33.4; P < 0.0001). Gastrointestinal adverse events were more often reported with semaglutide (n = 30) than with placebo (n = 15). Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. ClinicalTrials.gov registration: NCT04889183 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“The effect of semaglutide on UACR was fully present at week 20, 4 weeks after up-titration to the maximum The GLP1-RA semaglutide demonstrated a reduction in cardio-vascular outcomes in patients with cardiovascular disease with or without diabetes 15,16 .”
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146 · cited 1×
“Many patients with obesity develop type 2 diabetes 3 .”
Self-citationOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 3×
“In the FLOW trial, which is the only dedicated GLP-1 RA kidney outcome trial to date, semaglutide 1.0 mg once weekly reduced UACR by 32% 17 .”
InfluentialKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654 · cited 1×
“However, obesity can also cause kidney impairment through non-diabetes-related pathophysiological mechanisms, including hemodynamic perturbations, leading to increased intra-glomerular pressure and hyperfiltration, inflammation and oxidative stress 6,7 .”
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationGarofalo, C., Borrelli, S., Minutolo, R., Chiodini, P., De Nicola, L., & Conte, G. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.013 · Cited by 363 · cited 1×
“Both conditions increase the risk of progressive kidney function loss and adverse cardiovascular outcomes 4,5 .”
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306 · cited 2×
“Similarly, in the SURPASS-4 trial, tirzepatide, a combined glucose inhibitory peptide (GIP)/GLP-1 receptor agonist, reduced eGFR decline compared to insulin in patients with type 2 diabetes at high cardiovascular risk with similar weight loss as observed in our study 27 .”
Self-citationObesity and chronic kidney disease
Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, X., Gang, X., & Wang, G. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2022 · Cited by 267 · cited 1×
“However, obesity can also cause kidney impairment through non-diabetes-related pathophysiological mechanisms, including hemodynamic perturbations, leading to increased intra-glomerular pressure and hyperfiltration, inflammation and oxidative stress 6,7 .”
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03015-5 · Cited by 238
Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., Inrig, J., Komers, R., Mercer, A., Noronha, I. L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00569-x · Cited by 224
Self-citationTuttle, K. R., Hauske, S. J., Canziani, M. E., Caramori, M. L., Cherney, D., Cronin, L., Heerspink, H. J. L., Hugo, C., Nangaku, M., Rotter, R. C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02408-x · Cited by 206
Self-citationMann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200 · cited 1×
“Specifically, a pre-specified analysis of the FLOW trial showed consistent benefits on UACR, eGFR decline and clinical outcomes in participants using or not using SGLT2 inhibitors at baseline 24 .”
Self-citationOshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050723 · Cited by 176
Self-citationNeuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168 · cited 1×
“Furthermore, a meta-analysis of GLP-1 RA trials in patients with type 2 diabetes recently concluded that combination treatment with both classes of agents is likely to provide additional benefits in reducing the risks of cardiovascular and kidney outcomes 25 .”
Self-citationApperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 165
Self-citationHeerspink, H. J. L., Kiyosue, A., Wheeler, D. C., Lin, M., Wijkmark, E., Carlson, G. F., Mercier, A., Åstrand, M., Ueckert, S., Greasley, P. J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02230-4 · Cited by 165
Self-citationRenal hyperfiltration related to diabetes mellitus and obesity in human disease
Sasson, A. N. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i1.1 · Cited by 158
Li, K., Zou, J., Ye, Z., Di, J., Han, X., Zhang, H., Liu, W., Ren, Q., & Zhang, P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163907 · Cited by 127
Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125
Heerspink, H. J. L., Apperloo, E., Davies, M., Dicker, D., Kandler, K., Rosenstock, J., Sørrig, R., Lawson, J., Zeuthen, N., & Cherney, D. (2023) · Diabetes Care · doi:10.2337/dc22-1889 · Cited by 98 · cited 1×
“Previous studies, mainly in patients with type 2 diabetes, had already shown that GLP-1 RAs reduce UACR by 30–40% 19–22 .”
Self-citationObesity and kidney disease: hidden consequences of the epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., Li, P. K., García-García, G., Benghanem-Gharbi, M., Bollaert, R., Dupuis, S., Erk, T., Kalantar‐Zadeh, K., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.10.019 · Cited by 73
The Effects of Bariatric Surgery on Renal Outcomes: a Systematic Review and Meta-analysis
Bilhă, Ş., Nistor, I., Nedelcu, A., Kanbay, M., Scripcariu, V., Timofte, D. V., Siriopol, D. C., & Covic, A. C. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3416-4 · Cited by 69
Heerspink, H. J. L., Ninomiya, T., Persson, F., Brenner, B. M., Brunel, P., Chaturvedi, N., Desai, A. S., Haffner, S. M., Mcmurray, J. J. V., Solomon, S. D., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12600 · Cited by 57
Self-citationObesity and kidney disease: Hidden consequences of the epidemic
Kovesdy, C. P., Furth, S. L., & Zoccali, C. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2016.11.001 · Cited by 56
Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0261 · Cited by 53 · cited 1×
“Notably, changes in body weight did not correlate with eGFR, whether estimated with creatinine or with cystatin-C 29 .”
Self-citationde Zeeuw, D., Renfurm, R. W., Bakris, G. L., Rossing, P. R., Perkovic, V., Hou, F. F., Nangaku, M., Sharma, K., Heerspink, H. J. L., García-Hernández, A., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30289-4 · Cited by 52
Self-citationTuttle, K. R., Lakshmanan, M. C., Rayner, B., Zimmermann, A. G., Woodward, B., & Botros, F. T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13668 · Cited by 42
Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials
Heerspink, H. J. L., Cherney, D., Gafor, A. H. A., Górriz, J. L., Pérgola, P. E., Tang, S. C. W., Desch, M., Iliev, H., Sun, Z., Steubl, D., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000418 · Cited by 41
Self-citationMeasuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio
Chagnac, A., & Friedman, A. N. (2024) · Kidney Medicine · doi:10.1016/j.xkme.2024.100804 · Cited by 35
Fawaz, S., Alonso, A. M., Qiu, Y., Ramnath, R. D., Stowell-Connolly, H., Gamez, M., May, C., Down, C. J., Coward, R. J., Butler, M. J., et al. (2024) · Diabetes · doi:10.2337/db23-0455 · Cited by 29
Clerté, M., Wagner, S., Carette, C., Sartorius, A. B., Vilaine, É., Alvarez, J., Abé, E., Barsamian, C., Czernichow, S., & Massy, Z. A. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2016.10.002 · Cited by 26
Apperloo, E. M., Cherney, D. Z. I., Kuhlman, A. B., Mann, J. F. E., Rasmussen, S., Rossing, P., Tuttle, K. R., Vrhnjak, B., & Heerspink, H. J. L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae150 · Cited by 20
Self-citationStevens, J., Wessels, A. M. A., Roggeveld, J., et al. (2020) · Bioanalysis · doi:10.4155/bio-2020-0122 · Cited by 8
Self-citationHeerspink, H. J. L., Ninomiya, T., Persson, F., Brenner, B. M., Brunel, P., Chaturvedi, N., Desai, A. S., Haffner, S. M., McMurray, J. J. V., Solomon, S. D., et al. (2016) · Research Bank (Australian Catholic University) · Cited by 5
Self-citation
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
“302,303 The SURPASS-4 trial 304 revealed that tirzepatide signi fi cantly reduced composite kidney endpoints by 40% and improved the annual eGFR decline by 2.2 mL/min per 1.73 m 2 per year.”
InfluentialObesity: Recent Advances and Future Perspectives
Janić, M., Janež, A., El‐Tanani, M., & Rizzo, M. (2025) · Biomedicines · doi:10.3390/biomedicines13020368 · Cited by 97
From Intention To Implementation: Automating Biomedical Research via LLMs
Luo, Y., Shi, L., Li, Y., Zhuang, A., Gong, Y., Liu, L., & Lin, C. (2024) · arXiv · doi:10.48550/arxiv.2412.09429 · Cited by 53
Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.009 · Cited by 49
Metadata
- Authors
- Apperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., Hoogenberg, K., van Beek, A. P., Verhave, J., Ahmed, S. B., Schmieder, R. E., Wanner, C., Cherney, D. Z. I., Jongs, N., & Heerspink, H. J. L.
- Affiliations
- University Medical Center Groningen (NL)
- Bellvitge University Hospital (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Isala (NL)
- Ziekenhuis Groep Twente (NL)
- Martini Ziekenhuis (NL)
- Rijnstate Hospital (NL)
- University of Alberta (CA)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Würzburg (DE)
- University of Toronto (CA)
- Corresponding author
- Heerspink, Hiddo J. L.
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-10-25
- Volume
- 31
- Issue
- 1
- Pages
- 278-285
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4403750647
- Cited by
- 120
- References
- 45
- Citations by year
- 2026: 51 · 2025: 64 · 2024: 5
- FWCI
- 34.22
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, obesity, overweight, chronic kidney disease, albuminuria, albumin-creatinine ratio, GIP/GLP-1 receptor agonist, weight loss, systolic blood pressure, gastrointestinal adverse effects, non-diabetic CKD, kidney disease progression, body mass index, estimated glomerular filtration rate, chronic glomerulonephritis
- MeSH terms
- Semaglutide, Adult, Aged, Albuminuria, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Obesity, Body Mass Index, Overweight, Renal Insufficiency, Chronic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.